Eversept Partners LP raised its stake in argenx SE – (NASDAQ:ARGX) by 22.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 48,264 shares of the company’s stock after purchasing an additional 8,930 shares during the period. argenx makes up approximately 1.9% of Eversept Partners LP’s holdings, making the stock its 14th biggest position. Eversept Partners LP owned 0.15% of argenx worth $6,833,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of the business. Artisan Partners Limited Partnership lifted its holdings in shares of argenx by 143.6% during the 1st quarter. Artisan Partners Limited Partnership now owns 770,336 shares of the company’s stock worth $96,169,000 after acquiring an additional 454,046 shares during the period. Marshall Wace North America L.P. acquired a new stake in shares of argenx during the 1st quarter worth about $27,705,000. FMR LLC increased its position in shares of argenx by 6.1% during the 1st quarter. FMR LLC now owns 3,699,956 shares of the company’s stock worth $461,903,000 after purchasing an additional 212,904 shares in the last quarter. Redmile Group LLC increased its position in shares of argenx by 6.0% during the 1st quarter. Redmile Group LLC now owns 1,019,061 shares of the company’s stock worth $127,220,000 after purchasing an additional 58,100 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of argenx by 91.2% during the 2nd quarter. Renaissance Technologies LLC now owns 82,400 shares of the company’s stock worth $11,666,000 after purchasing an additional 39,300 shares in the last quarter. 69.54% of the stock is owned by hedge funds and other institutional investors.
ARGX traded down $0.96 during midday trading on Friday, hitting $124.25. The company had a trading volume of 104 shares, compared to its average volume of 131,965. The company has a debt-to-equity ratio of 0.01, a quick ratio of 14.29 and a current ratio of 9.37. The company has a market capitalization of $4.68 billion, a PE ratio of -52.84 and a beta of 1.25. argenx SE – has a twelve month low of $63.81 and a twelve month high of $150.92. The firm’s 50-day simple moving average is $136.49 and its 200-day simple moving average is $131.53.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Recommended Story: Stop Order
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.